TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis
Metrics: PDF 1213 views | HTML 1888 views | ?
Yang Zhang1, Pengcheng Cai1, Tao Liang1, Lin Wang1,2 and Lihua Hu1
1Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Lihua Hu, email: firstname.lastname@example.org
Lin Wang, email: email@example.com
Keywords: TIM-3, meta-analysis, solid tumor, prognostic marker, overall survival
Received: August 29, 2016 Accepted: February 21, 2017 Published: March 07, 2017
Accumulated studies have demonstrated the important role of T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) in various solid tumors and indicated its correlation with patients’ survival. To further verify the prognostic significance of TIM-3 in cancer patients and its correlation with tumor, we performed this meta-analysis including seven studies searched from PubMed, Web of Science, and Embase till July 2016. A total of 869 patients were used to analyze the association between TIM-3 expression and patients’ overall survival (OS). The pooled results showed that higher expression of TIM-3 was significantly correlated to shorter OS (7 studies, HR=1.89; 95% CI: 1.38-2.57; P< 0.001). In addition, higher TIM-3 expression was associated with advanced tumor stage (3 studies, III/IV vs. I/II, RR=2.02; 95% CI: 1.45–2.81; P< 0.001). In conclusion, our study highlights the role of TIM-3 as a potential prognostic marker and a promising therapeutic target in solid tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.